Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1 Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis
Brain metastasis (BM) is a common complication in non-small cell lung cancer (NSCLC), which associates with poor prognosis. Recently, immune checkpoint inhibitors (ICIs) has revolutionized the treatment of tumors. Programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors could produce a...
Main Authors: | Jiamin SHENG, Xiaoqing YU, Hui LI, Yun FAN |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2020-11-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.31 |
Similar Items
-
Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for
Non-small Cell Lung Cancer
by: Sixuan WU, et al.
Published: (2019-07-01) -
Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01) -
Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01) -
A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01) -
Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
by: Zhiyu HUANG, et al.
Published: (2015-11-01)